Time: 10am CDT / 8am PST / 4pm London / 5pm Amsterdam-Paris

"Illuminating New Frontiers: Cracking the Undruggable Code" invites you on a groundbreaking journey across the evolving landscape of drug discovery. This three-day virtual event unites trailblazers in science and industry to explore how innovative approaches are reshaping our ability to tackle "undruggable" targets. From the complexities of the RAS pathway and the intricacies of protein-protein interactions to the pioneering fields of targeted protein degradation/induced proximity and RNA targeting, each day illuminates a different frontier of therapeutic potential.

We stand at the cusp of a new era, where challenges become opportunities for breakthroughs that extend beyond conventional boundaries. This event is a testament to the power of collaboration and innovation in unveiling new therapeutic strategies, offering hope for untreatable conditions. Join us as we navigate the cutting-edge of science, inspiring a future where every target is within our reach, and no one is left without options.

Day 1: Rethinking Undruggable Targets: New Insights into RAS and Protein Interactions

In the realm of drug discovery, certain targets have long been deemed "undruggable" due to their complex nature and the technical challenges associated with modulating them therapeutically. Among these, the RAS pathway stands out as an important element in cell signaling implicated in numerous cancers and diseases. Historically deemed undruggable due to its complex biochemistry and lack of suitable binding sites, RAS has recently witnessed a paradigm shift. Recent innovations in molecular biology - coupled with breakthroughs in drug design and technology - have challenged the notion that the RAS pathway is undruggable, leading to the development and market approval of RAS-targeting therapeutics. Similarly, protein-protein interactions (PPI) - key elements of RAS signaling - represent untapped therapeutic potential, offering avenues to intervene in disease processes in ways previously deemed infeasible.

In this session, we will explore the latest research targeting the RAS/MEK/ERK signaling pathway and learn about novel approaches being developed to manipulate and measure PPIs within RAS and other signaling networks. Join the conversation and engage directly with the experts in a live round-table discussion following the presentations.

_1728210878944